The XPO1 Inhibitor KPT-8602 Synergizes with Dexamethasone in Acute Lymphoblastic Leukemia.
Delphine VerbekeSofie DemeyerCristina PrietoCharles E de BockJolien De BieOlga GielenKris JacobsNicole MentensBronte Manouk VerhoevenAnne UyttebroeckNancy BoeckxKim De KeersmaeckerJohan MaertensHeidi SegersJan CoolsPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
Our preclinical study demonstrates that KPT-8602 enhances the effects of dexamethasone to inhibit B-ALL and T-ALL cells via NR3C1- and E2F-mediated transcriptional complexes, allowing to achieve increased dexamethasone effects for patients.
Keyphrases
- acute lymphoblastic leukemia
- high dose
- low dose
- end stage renal disease
- induced apoptosis
- ejection fraction
- newly diagnosed
- chronic kidney disease
- peritoneal dialysis
- gene expression
- prognostic factors
- cell cycle arrest
- stem cells
- transcription factor
- oxidative stress
- cell proliferation
- bone marrow
- cell therapy
- patient reported
- pi k akt